European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastic agents - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy.dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - aripiprazole - orodispersible tablet - aripiprazole 10 mg - psycholeptics

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - aripiprazole - orodispersible tablet - aripiprazole 15 mg - psycholeptics

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - aripiprazole - orodispersible tablet - aripiprazole 30 mg - psycholeptics

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cabazitaxel, quantity: 60 mg - injection, concentrated - excipient ingredients: polysorbate 80; ethanol absolute - cabazitaxel accord in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen. .

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - lenalidomide - multiple myeloma - immunosuppressants - multiple myelomalenalidomide accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.lenalidomide accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.lenalidomide accord in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.follicular lymphomalenalidomide accord in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cisplatin, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: water for injections; sodium chloride; hydrochloric acid; sodium hydroxide - cisplatin accord may be used as a monotherapy or in combination with other chemotherapeutic agents in the treatment of:,? metastatic non-seminomatous germ cell carcinoma,? advanced stage, refractory ovarian carcinoma,? advanced stage, refractory bladder carcinoma,? refractory squamous cell carcinoma of the head and neck

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cisplatin, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: sodium hydroxide; sodium chloride; water for injections; hydrochloric acid - cisplatin accord may be used as a monotherapy or in combination with other chemotherapeutic agents in the treatment of:,? metastatic non-seminomatous germ cell carcinoma,? advanced stage, refractory ovarian carcinoma,? advanced stage, refractory bladder carcinoma,? refractory squamous cell carcinoma of the head and neck

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cisplatin, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - cisplatin accord may be used as a monotherapy or in combination with other chemotherapeutic agents in the treatment of:,? metastatic non-seminomatous germ cell carcinoma,? advanced stage, refractory ovarian carcinoma,? advanced stage, refractory bladder carcinoma,? refractory squamous cell carcinoma of the head and neck

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cisplatin, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: sodium chloride; sodium hydroxide; water for injections; hydrochloric acid - cisplatin accord may be used as a monotherapy or in combination with other chemotherapeutic agents in the treatment of:,? metastatic non-seminomatous germ cell carcinoma,? advanced stage, refractory ovarian carcinoma,? advanced stage, refractory bladder carcinoma,? refractory squamous cell carcinoma of the head and neck